Webinar
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Friday, April 10, 2026 | 11:00 AM EST
Relying on exposure data alone is a leading cause of translational failure. To truly predict clinical outcomes, you must bridge the gap between drug concentration and biological effect. This webinar provides a masterclass in integrating pharmacokinetics (PK) with pharmacodynamics (PD) to transform raw data into a roadmap for candidate success.
Register Now
In this webinar you will learn:
- Mechanistic Modeling: Moving beyond descriptive data to build predictive exposure–response models.
- Strategic Biomarker Integration: Selecting and validating the right markers to confirm target engagement.
- Dose Optimization: Pinpointing the therapeutic window for NCEs, large molecules, and ADCs.
- Cross-Modality Insights: Navigating the unique PK/PD challenges of diverse therapeutic platforms.
- Risk Mitigation: Solidifying First-in-Human (FIH) projections and narrowing the "translational gap."
- Translational Confidence: Hard-coding predictive power into candidate selection to streamline regulatory transitions.
Through practical examples and case studies, you will see how early PK/PD integration transforms raw data into a clear roadmap—reducing program risk and accelerating your transition from bench to clinic.
Register Now
About The Presenters:
Rekha Pal, PhD, Senior Director, Scientific Engagement, Crown Bioscience
Dr. Rekha Pal is a highly accomplished cancer biologist specializing in immuno-oncology, translational research, and the tumor microenvironment. With extensive experience across both discovery and clinical development, she has led programs for targeted therapies and immune checkpoint inhibitors, including pivotal work on the molecular targets of thalidomide derivatives like pomalidomide and lenalidomide. Dr. Pal excels at bridging the gap between bench and clinic by developing complex cell-based disease models—such as organoids and primary human cell cultures—and collaborating with computational biologists to correlate genomic signatures with drug interactions for biomarker selection. Her multifaceted expertise at Crown Bioscience encompasses the design of in vitro and in vivo studies, the establishment of clinical protocols for patient sample analysis, and the successful navigation of IRB and IACUC regulatory frameworks to accelerate drug development programs.
